P000054/S075: INFUSE BONE GRAFT
FDA’s recorded scope: Approval for a change to the potency testing of rhBMP-2 used in the manufacturing of INFUSE Bone Graft.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 16 FDA records to the applicant name MEDTRONIC SOFAMOR DANEK USA, INC.. The collection includes 7 510(k) clearances. 5 entries are PMA supplements. 4 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jan 7, 2026 to Oct 29, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NEK appears in 5 of the 16 linked filings. The collection spans 6 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P000058, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 1800 Pyramid Pl., Memphis, TN, 38132, US. Recorded on K262572, decision dated Oct 29, 2026.
Intervertebral Fusion Device With Bone Graft, Lumbar; Filler, recombinant human bone morphogenetic protein, collagen scaffold, osteoinduction; Filler, recombinant human bone morphogenetic protein, collagen scaffold with metal prosthesis, osteoinduction; Electrosurgical, Cutting & Coagulation & Accessories; Thoracolumbosacral Pedicle Screw System; Posterior Cervical Screw System.
FDA’s recorded scope: Approval for a change to the potency testing of rhBMP-2 used in the manufacturing of INFUSE Bone Graft.
FDA’s recorded scope: Approval for a change to the potency testing of rhBMP-2 used in the manufacturing of INFUSE Bone Graft.
FDA’s recorded scope: Approval to offer an alternatively configured Infuse Bone Graft kit in which the sterile water for injection (sWFI) vials, syringes, and needles have been removed from the kit, as well as minor labeling changes associated with this alternative kit configuration.
FDA’s recorded scope: Approval to offer an alternatively configured Infuse Bone Graft kit in which the sterile water for injection (sWFI) vials, syringes, and needles have been removed from the kit, as well as minor labeling changes associated with this alternative kit configuration.
FDA’s recorded scope: addition of an alternate testing facility and relocation of relevant laboratories to a new building
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
MedtechLedger links 3 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 3 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.
| Recall / product | Company | Classification | Report date | Source |
|---|---|---|---|---|
| MEDTRONIC SOFAMOR DANEK USA, INC. | Class II | Oct 21, 2026 | FDA | |
| MEDTRONIC SOFAMOR DANEK USA, INC. | Class II | Oct 21, 2026 | FDA | |
| MEDTRONIC SOFAMOR DANEK USA, INC. | Class II | Dec 3, 2025 | FDA |
Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.
Source updated Nov 11, 2026. Retrieved Nov 21, 2026.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.